Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and integrated hybrid continuous purification processes. Under the deal Transcenta will receive upfront, milestone and future royalties; EirGenix will implement HiCB to serve CDMO clients pursuing intensified and continuous manufacturing. Transcenta framed the agreement as a route to expand global access and reduce cost of biologics while reinvesting proceeds into its R&D pipeline. EirGenix emphasized the move as a way to offer clients advanced continuous manufacturing solutions in Taiwan and beyond. Clarification: continuous biomanufacturing integrates upstream perfusion and downstream continuous purification to increase productivity and reduce facility footprint versus traditional batch runs.